AIM ImmunoTech Announces Release of the Next CEO Corner Segment

Core Insights - AIM ImmunoTech Inc. has published a new CEO Corner segment on its website, featuring an overview of positive data from a Phase 1 clinical trial that investigates the use of Ampligen in combination with paclitaxel for treating early-stage triple-negative breast cancer [1] Company Overview - AIM ImmunoTech Inc. is an immuno-pharmaceutical company dedicated to the research and development of therapeutics aimed at treating various cancers, immune disorders, and viral diseases, including COVID-19 [2] - The company's lead product is Ampligen® (rintatolimod), which is a first-in-class investigational drug that acts as a dsRNA and highly selective TLR3 agonist immuno-modulator, demonstrating broad-spectrum activity in clinical trials for significant global health issues [2]